Stratis (STRAT) Price Booms on Partnership with MediConnect
Stratis (STRAT) has extended its price rally, briefly going over $1.50 on news of a partnership with MediConnect, a company offering blockchain solutions tailored to the medical industry. The startups announced in a recent press release, saying MediConnect aims to increase traceability and prescription filling at multiple pharmacies by using a tamper-proof distributed ledger.
“MediConnect will become another customer of Stratis, utilizing our consultancy services to build and deliver a bespoke blockchain solution set to revolutionize the medical industry,” commented Stratis founder and CEO Chris Trew.
MediConnect will use the technologies offered by the Stratis platform, including distributed ledger management, a full node in C#, and smart contracts in C#.
“Stratis was a natural selection for us. We have already established relationships within the medical industry and government to understand the real problems within the space. This has enabled us to design such a solution, leveraging Stratis’ solutions in a familiar programming language,” MediConnect director Dexter Blackstock stated.
MediConnect will start its pilot program with 8 to 10 pharmacies. Before that, it will conduct an initial coin offering (ICO) using the Stratis platform.
The STRAT price got an additional boost from the addition of Stratis C# Full Node to Microsoft’s Azure marketplace.
STRAT reached $1.48 as of 9:30 UTC on Thursday, adding 40% overnight. The asset, which moved close to $20 during its growth peak early in 2018, was one of the more successful ICOs, still trading significantly above the sub-penny price of the offering. During recent sell-offs, STRAT hit lows of around $0.56 on December 15, extending the growth to 128% in the past week. Like many altcoins, STRAT got a boost from the rising Bitcoin (BTC) prices.
Neither the author nor the publication assumes any responsibility or liability for any investments, profits, or losses made as a result of this information. Cryptocurrency trading and investing are risky propositions, and market participants are advised to always conduct thorough research.
Back to the list